Catalogue en ligne Centre d'Information et de Documentation <br>du CRA Rhône-Alpes

Brief Report: Acamprosate in Fragile X Syndrome / Craig ERICKSON in Journal of Autism and Developmental Disorders, 40-11 (November 2010)

Titre :	Brief Report: Acamprosate in Fragile X Syndrome
Type de document :	Texte imprimé et/ou numérique
Auteurs :	Craig ERICKSON, Auteur ; Jennifer E. MULLETT, Auteur ; Christopher J. MCDOUGLE, Auteur
Année de publication :	2010
Article en page(s) :	p.1412-1416
Langues :	Anglais (eng)
Mots-clés :	Acamprosate Fragile X syndrome mGluR5 Language Irritability
Index. décimale :	PER Périodiques
Résumé :	Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.
En ligne :	http://dx.doi.org/10.1007/s10803-010-0988-9
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=114